Modality
Gene Editing
MOA
PLK4i
Target
Menin
Pathway
JAK/STAT
MesoGBMEndometrial Ca
Development Pipeline
Preclinical
~Mar 2014
→ ~Jun 2015
Phase 1
~Sep 2015
→ ~Dec 2016
Phase 2
~Mar 2017
→ ~Jun 2018
Phase 3
~Sep 2018
→ ~Dec 2019
NDA/BLA
Mar 2020
→ Jul 2027
NDA/BLACurrent
NCT08362165
268 pts·Meso
2020-03→2027-07·Recruiting
268 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-07-221.3y awayPh3 Readout· Meso
Trial Timeline
Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2027-07-22 · 1.3y away
Meso
Recruiting|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08362165 | NDA/BLA | Meso | Recruiting | 268 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| LLY-8369 | Eli Lilly | Approved | Menin | |
| NVS-1475 | Novartis | Phase 2 | Menin | |
| AMG-2597 | Amgen | Phase 2/3 | CD38 | |
| VRT-9481 | Vertex Pharma | Phase 1/2 | Menin | |
| Olpainavolisib | Moderna | Phase 1 | Menin | |
| Riluinavolisib | Moderna | NDA/BLA | KIF18A | |
| Cevimavacamten | Denali | NDA/BLA | Menin | |
| Sovacagene | Relay Therapeutics | Phase 1/2 | Menin | |
| ZEA-9089 | Zealand Pharma | Phase 2/3 | Menin | |
| SND-5878 | Syndax | NDA/BLA | Menin |